Resources

It’s Spring Statement week and we have a webinar on what it means for the sector this Friday; also in this blog - why VPAG needs sorting and a new Series C raise for a BIA member, Brainomix.

In this blog, BIA CEO Steve Bates OBE gives his take on the announcement that the UK government is consulting on introducing a new law to raise the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies' NHS sales revenues in the second half of 2025.

A big raise as next generation biotech leaders gather, NHS England is abolished, and global trade disputes touch on our industry.

This week, BIA was invited by the Foreign Secretary to represent UK life sciences in Japan. In Parliament, we're championing a robust industrial strategy. Our new report provides the data and real life experience on womens’ leadership in our sector, while a former Board BIA member joins Duran Duran (sort of).

Last week was a big one for UK life sciences, from the BIA Committee Summit shaping our sector’s future to major leadership changes at UKRI and NHS England. In this week’s update, I explore what these developments mean for our industry, alongside breakthroughs in AI, investment, and accessibility in healthcare.

In this week’s blog, HM Treasury considers ISA changes to enable tax support for growth, a new engineering biology regulatory group gives the UK a strategic edge and a key MHRA webinar on ILAP is upcoming.

 This week’s blog explores the dynamic intersection of life sciences, policy, and innovation. From groundbreaking collaborations in the UK to navigating the shifting IP landscape in North America, I reflect on how our sector continues to lead and adapt in a rapidly changing world.

The UK’s biotech sector continues to break new ground, from sustainable medicine manufacturing to AI-driven healthcare advancements. This week, I analyse key developments shaping the industry, including the launch of the Sustainable Medicine Manufacturing Innovation Programme, the BIA’s role in the government’s Spending Review, and the UK’s leadership in cultivated meat.

As Donald Trump returns to the White House, the biotech industry is assessing what his presidency means for investment and innovation. With the UK’s life sciences sector gaining strength, could this be the moment to turn uncertainty into opportunity?

Science Minister Vallance yesterday visited semiconductors and life sciences firms in Cambridgeshire, following his appointment as Oxford-Cambridge Innovation Champion

The BIA is driving progress across life sciences, from shaping policy in engineering biology and advocating for balanced perspectives in the Covid Inquiry to exhibiting UK innovation at JP Morgan Healthcare Week. 

UK dealmakers are at the heart of JPM, the Government rolls out AI plan and new MHRA Chair sets priorities.

In this guest blog, Christine Hockley, Managing Director at British Patient Capital, outlines the substantial long-term investment needed to scale innovations.

The global life science investment and media community are heading to the JPM Healthcare Conference next week and we’ll be keeping an eye on announcements and grants that impact our industry.

New legislation was laid in Parliament last Thursday to modernise the regulation of clinical trials in the UK.

Patients, the NHS and the Life Sciences sector set to benefit from new clinical trials framework being laid in parliament today.

As 2024 comes to a close, we’re proud to reflect on a year of championing the life sciences sector, from driving impactful policy changes to fostering connections across the UK and beyond. Dive into our key achievements, events, and milestones that shaped the year and set the stage for an exciting 2025.

As we engage as an Association in the development of the life science sector plan, the 10 year NHS plan and the UK’s industrial strategy this winter, this week I’ve been reflecting on what recent NHS announcements on adoption of innovation tell us.